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Ethics in practice
Making clinical decisions when the stakes are high and
the evidence unclear
Wendy Hu, Andrew Kemp, Ian Kerridge
Children with peanut allergy are often provided with adrenaline (epinephrine) in case of a severe
reaction. The probability of a life threatening reaction is low, however, and the criteria for provision
are controversial. How should the costs and benefits be balanced?
Case study 1
Dylan, a 20 month old boy, was referred to a paediatric
allergy clinic for assessment of his peanut allergy. At 12
months of age he developed facial contact urticaria to
peanut butter, which spontaneously resolved without
respiratory or other symptoms. Since then, he has not
had further reactions or eaten peanuts, although the
rest of the family often eat peanuts and nuts. Dylan is
regularly cared for by his grandparents and does not
attend a childcare centre. His skin prick tests show a 9
mm ( ≥ 3 mm is considered positive) reaction to
peanut.
The doctor recommended that he continue to
avoid peanuts and be reviewed annually with skin prick
testing. If the results remain positive without other
clinical reactions, Dylan will be considered for a formal
food challenge when he starts school. An emergency
adrenaline (epinephrine) autoinjector (self or carer
administered) was not recommended. Dylan’s mother
said, “I had heard about [autoinjectors] so I was waiting
to hear what the specialist would say. I suppose that if
you had to, you would give it, but I just can’t see it. I hate
seeing him have needles for any reason.”
Case study 2
Jarred is 23 months old and attended the same clinic.
At 9 months of age, peanut butter touched his face and
he developed local urticaria and lip and periorbital
swelling without respiratory or systemic symptoms. His
parents took him to the local hospital, where he was
placed on cardiorespiratory monitors and given two
adrenaline injections. He was then seen by a paediatric
allergist, who prescribed an adrenaline autoinjector.
Since then he has avoided peanuts and has not had
further reactions. Peanuts have been removed from the
household and the family’s diet. After Jarred’s
enrolment, the childcare centre he attends two days a
week completely banned peanuts, nuts, and any foods
labelled “may contain nuts.”
At this consultation, skin prick tests showed a 9 mm
reaction to peanut. Jarred’s parents were advised that
he should continue to avoid peanuts. Although his
mother was informed that the risk of death was
extremely low, she wished to continue Jarred’s
autoinjector prescription: “My biggest fear is that he
could be having a reaction and he can’t tell us . . . the
autoinjector allows me to feel more in control . . . it’s a
safety net so I’m not totally helpless.”
The issues
It will be no surprise to clinicians that patients with
similar clinical features can end up being managed dif-
ferently. Variation in medical practice may be deemed
appropriate or inappropriatew1 and stems from many
sources, some of which are unavoidable. Underlying
the decisions of individual doctors and patients is the
inherently uncertain nature of medical knowledge. In
our example of childhood food allergies, the
uncertainty is given a potent twist by a remote but
dreaded outcome—the death of a child. These factors
create a dilemma when weighing up the risk of a severe
reaction or anaphylaxis against possible responses.
Peanut allergy
Peanuts are a commonly eaten food and often
included in processed and pre-prepared foods. The
prevalence of peanut allergy is rising and was
estimated at 1.5% in a recent child population study.1
Peanuts have been identified as the most common pre-
cipitant for deaths from food induced anaphylaxis in
the United Kingdom,2 although not in children under
13 years of age.3 Currently, there is no effective immu-
notherapeutic or medical treatment, so management
strategies rely on avoidance of food allergens and
emergency treatment of severe reactions. Analyses of
fatal cases have suggested that deaths may be
prevented with early administration of adrenaline,2
leading to calls for adrenaline autoinjectors to be
widely available to children with food allergies and
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their carers.4 Although this response seems rational
and empirically sound, it camouflages persisting medi-
cal, scientific, and ethical uncertainties.5 w2
Medical uncertainties
Uncertainty is inevitable in medical practice.w3 For
example, the diagnosis of food allergy in both our cases
relies primarily on clinical history, but equivocal histo-
ries are not uncommon. Investigations for confirming
food allergy such as skin prick tests have limited
predictive value, and food challenges can trigger
serious allergic reactions.6 w4 Although the diagnosis of
peanut allergy in Dylan and Jarred is not in question,
clinical features cannot accurately predict whether they
would have a life threatening reaction if they ate
peanut products.7
Management uncertainties also exist. Although
avoiding trigger foods and treating serious reactions are
widely accepted, determining the degree of avoidance
required is difficult,w5 and the prescribing of adrenaline
autoinjectors is debated.w6 Published recommendations
vary from the assertion that autoinjectors should be
given to all patients with peanut allergy6 to statements
that they should be given only to patients who have had
moderate to severe reactions, including laryngeal
oedema, dyspnoea, and collapse, unless the patient cur-
rently has asthma or reactions to trace amounts of aller-
gen.8 Follow up studies have shown that even when
autoinjectors are prescribed they may be not be used
appropriately, or at all, for anaphylactic episodes.9 w7
To summarise, we cannot predict those at high risk
of serious reactions, it is difficult to know who to treat
and to what extent, and on a population basis, the evi-
dence for providing adrenaline autoinjectors to
prevent deaths from anaphylaxis is unclear.
Risks and values
Although families and the public may wish to hear that
there is no risk of childhood anaphylaxis or other feared
outcomes such as adverse reactions tomeasles vaccine, it
is not possible to prove a zero risk conclusively.w8 A sin-
gle case report of fatal anaphylaxis to nut in a 2 year old
is sufficient to say that a risk exists.10 Although the prob-
ability of death from anaphylaxis in young children is
very low, uncertainty about degrees of risk and scientific
disagreement over appropriate responses heightens
public perceptions of danger.w9
Various sources, including friends and family, mass
media, and lobby groups, and the way messages are con-
veyed can also modify how risks are interpreted.w10
Jarred’s emergency treatment at the local hospital is
likely to have influenced his parents’ perception of the
risk of severe reactions. Public perceptions of the risk of
childhood anaphylaxis are also increased by the
difficulty of controlling exposure to food, the unpredict-
ability of fatal outcomes, and the catastrophic and unjust
nature of child deaths. Our reactions reflect fundamen-
tal beliefs about societal obligations to protect the
vulnerable, and parental responsibilities to nurture and
ensure the safety of their children.11 Thus, risk is not a
value neutral probability but a socially mediated sense of
threat to a cherished section of society. As one
prominent UK allergist has stated, “There may be no
such thing as a definitely low risk peanut allergic child.”w6
Is it better to be safe than sorry?
It could be argued that we should do everything possi-
ble to keep allergic children safe. However, the value
that we attach to children does not, in itself, justify such
actions. Minimising risks to children incurs costs,
financial and otherwise, which may be unfairly borne
by many when benefits are granted to a few. Even for
those few, medical interventions of unproved effective-
ness can cause physical harm and give false hope.
However, this argument raises the question of how to
define and measure effectiveness, benefit, and costs.
In recent years, the medical profession has tended
to refer to evidence based medicine and randomised
controlled trials to show the effectiveness of interven-
tions. A randomised controlled trial to determine who
should be prescribed an autoinjector would be
difficult; the endpoint of death is rare and there are
many confounders, so an enormous study population
would be required for statistical validity. It is doubtful
whether there is sufficient equipoise to ethically
support such a trial. Even if such a trial were
conducted, the answers are likely to be expressed as
probabilities—whether an intervention is more or less
likely to be effective. Although valuable, this type of
information is unlikely to reduce therapeutic uncer-
tainty to a level that will satisfy many parents and doc-
tors, and narrowly defined quantitative analyses will fail
to include benefits valued by families such as Jarred’s.
In such situations, it could be argued that clinical
decisions should be based on parental preferences and
notions of benefit. Parents are accepted proxy decision
makers for their children; they are expected to act in
their child’s best interests and are in the best position to
weigh up the consequences to their children and
themselves.11 Parents are also responsible for imple-
menting any interventions and may have a better
appreciation of potential risks, which may not be
anticipated by others. More generally, patient partici-
pation in decision making promotes trust between
patients and doctors and may result in greater satisfac-
tion with care.w11 The idea that differing notions of risk
and benefit should be accommodated is reflected in
the evolving literature on risk; the emphasis is shifting
from correcting public “misperceptions” to acknowl-
edging that lay perceptions of risk have their own
validity and logic.12
However, if broader definitions of benefit are to be
accepted, wider definitions of cost must also be consid-
ered. The financial cost of providing every child under
16 years old who has peanut allergy in Australia with
two autoinjectors has been estimated at $A51.7m
(£20.1m, €29.7m) for each life saved.7 Rigorously mini-
mising accidental exposure and carrying an autoinjec-
tor requires families to be in a continual state of
hypervigilance and may reduce their quality of life.13 14
Keeping children “safe’’ may also mean restricting their
activities and opportunities to develop independ-
ence.w12 Although parents may agree to these burdens
in return for indefinite benefits, others can become
involved. Teachers and child carers may be obliged to
undertake training to recognise reactions and adminis-
ter adrenaline, and the choices of other parents and
children will be restricted by nut and peanut bans at
schools and childcare centres. Ultimately, society as a
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whole will bear an opportunity cost when resources are
not allocated so that benefits will be maximised to all.
Thus it could be argued that at a certain level of
response, the costs of minimising the risk of food ana-
phylaxis will outweigh the likely benefits. However, the
point at which such a threshold lies depends on how
the consequences are viewed, and the societal values
inherent in such evaluations. Children occupy a special
place in modern society, such that their safety and
access to education and health care are viewed as
priorities. Accordingly, the public has much sympathy
for attempts to reduce risks to children and with
parental predicaments created by such attempts. An
argument can therefore be made on sociocultural
grounds that we all gain from efforts to prevent a
child’s death, justifying the liberal provision of adrena-
line autoinjectors and public health measures to
restrict exposure to peanuts. A precautionary
approach could then be acceptable, even if costs are
borne by many and the benefits are unquantifiable.
Conclusions
Childhood peanut allergy presents the possibility of a
rare but feared outcome without clear evidence to
guide management choices. As a result, a range of
clinical decisions could be justified. In such cases, the
best response for doctors could be to engage families
in a process of negotiation that acknowledges
uncertainties, invites and considers all relevant
viewpoints, and examines their basis non-judgmentally.
Acknowledging uncertainty does not mean that
doctors should constantly equivocate; patients may
interpret this as meaning “there is nothing to be done”
or that “it is simply a matter of chance.” When giving
advice, doctors might consider the likely effect of
different recommendations, possible costs and harms
from various interventions, and the values of both the
family and the broader community. They should be
prepared to explain their reasoning, while recognising
that parents and children may value options differently.
Whatever is decided, providing information and
support, and responding sensitively to parental anxiety
remains essential.
This approach to the doctor-patient relationship
implies commitment, trust, and open communication.
If the preferences of patients and doctors are to be
taken into account, practices are likely to vary between
individual cases. Doctors may have to accept that in a
pluralistic world, there will be varying trade-offs
between effective, equitable, or cost efficient goals and
between the interests of particular families and of
greater society. In situations of uncertainty, clinicians
can feel burdened by a perceived need to reconcile
competing or incommensurable interests. Beyond
finding pragmatic solutions within the clinical setting,
the whole responsibility for resolving these interests
cannot be shouldered by individual doctors but should
be shared by all stakeholders.
We thank the parents of Dylan and Jarred for contributing their
stories to this article.
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Summary points
Peanut allergy is an increasingly common problem.
The risk of anaphylaxis is difficult to predict
Providing adrenaline autoinjectors to every child with food allergy is
costly and criteria for provision are uncertain
Risk perceptions are influenced by the value society places on
children’s lives
Management should be decided with parents after discussing the
uncertainties
Endpiece
Should life be longer?
It would seem important to devote more of the
energies of man to improving the quality of life, so
that it may be joyous, or noble, or creative.
Otherwise, existence is nothing but the bored
molecular unwinding of a dismal biological clock.
Should life be longer than it is? Yes—if it has
charm, grace, purpose, or productivity. But what if
it is empty, sullen, frustrated, ignoble? One can
weep for the death of Christ or Schubert, but surely
not for the end of Caligula or Hitler.
Louis Lasagna,
clinical pharmacologist, 1923-2003
Claus A Pierach, professor of medicine,
Minnesota, USA
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